A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Slides:

Advertisements

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Advertisements

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation Andrea L.H. Arnett, MD, PhD, Kenneth.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis Hyun Lee, MD,

Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients after Trimodality Therapy Aditya Juloori, BS, Susan.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective.

Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma:

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Patterns of Cardiac Perfusion Abnormalities After Chemoradiotherapy in Patients with Lung Cancer Isis W. Gayed, MD, H Helen Liu, PhD, Xiong Wei, MD,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy.

Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Liru He, MD, Pamela K. Allen, PhD, Adam.

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma Mitchell Machtay, MD, Rebecca Paulus, BS, Jennifer.

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non– Small-Cell Lung Cancer Seung Jun Lee, MD, Jinwoo Lee, MD, Young.

Association between Systemic Chemotherapy before Chemoradiation and Increased Risk of Treatment-Related Pneumonitis in Esophageal Cancer Patients Treated.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Carcinoma of the esophagus: Prognostic significance of histologic type

Primary Small Cell Carcinoma of the Esophagus

PD6-1-6: Mid-course resimulation for small cell lung cancer patients receiving definitive chemoradiation: sparing of normal lung and esophagus without.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Improved Long-Term Outcome With Chemoradiotherapy Strategies in Esophageal Cancer Stephen G. Swisher, MD, Wayne Hofstetter, MD, Ritsuko Komaki, MD, Arlene.

Robert Comis, MD, The Passing of a “Lung Man”

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing Liao, MD, Weiye Deng, MD, Cai Xu, MD, Ritsuko Komaki, MD, Mariela Blum, MD, Wayne L. Hofstetter, MD, Linus Ho, MD, PhD, Steven H. Lin, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 6, Pages 1001-1010 (June 2017) DOI: 10.1016/j.jtho.2017.03.017 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Identification of included and excluded patients with esophageal cancer receiving chemoradiotherapy (CRT). AC, adenocarcinoma; SCC, squamous cell carcinoma; PET, positron emission tomography. Journal of Thoracic Oncology 2017 12, 1001-1010DOI: (10.1016/j.jtho.2017.03.017) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Disease-free survival and overall survival of the induction chemotherapy (IC) group versus the non-IC group. Journal of Thoracic Oncology 2017 12, 1001-1010DOI: (10.1016/j.jtho.2017.03.017) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Disease-free survival and overall survival of the high-risk group versus the low-risk group. Journal of Thoracic Oncology 2017 12, 1001-1010DOI: (10.1016/j.jtho.2017.03.017) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Disease-free survival of the induction chemotherapy (IC) group versus the non-IC group in different risk groups before and after propensity score matching. (A and B) High-risk group. (C and D) Low-risk group. Journal of Thoracic Oncology 2017 12, 1001-1010DOI: (10.1016/j.jtho.2017.03.017) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplemental Data 3 Figure 1. Overall survival curves of IC group versus non-IC group in different risk group before and after propensity score-matching (high-risk: A and B; low-risk: C and D). Journal of Thoracic Oncology 2017 12, 1001-1010DOI: (10.1016/j.jtho.2017.03.017) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplemental Data 4 Figure 2. Survival curves of IC group versus non-IC group in different risk group in patients with adenocarcinoma (high-risk: A and B; low-risk: C and D). Journal of Thoracic Oncology 2017 12, 1001-1010DOI: (10.1016/j.jtho.2017.03.017) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions